195 related articles for article (PubMed ID: 10188883)
41. Bryostatin-1 stimulates the transcription of cyclooxygenase-2: evidence for an activator protein-1-dependent mechanism.
De Lorenzo MS; Yamaguchi K; Subbaramaiah K; Dannenberg AJ
Clin Cancer Res; 2003 Oct; 9(13):5036-43. PubMed ID: 14581379
[TBL] [Abstract][Full Text] [Related]
42. Effect of pharmacologic manipulation of protein kinase C by phorbol dibutyrate and bryostatin 1 on the clonogenic response of human granulocyte-macrophage progenitors to recombinant GM-CSF.
McCrady CW; Staniswalis J; Pettit GR; Howe C; Grant S
Br J Haematol; 1991 Jan; 77(1):5-15. PubMed ID: 1998597
[TBL] [Abstract][Full Text] [Related]
43. Autocrine and paracrine effects of an ES-cell derived, BCR/ABL-transformed hematopoietic cell line that induces leukemia in mice.
Peters DG; Klucher KM; Perlingeiro RC; Dessain SK; Koh EY; Daley GQ
Oncogene; 2001 May; 20(21):2636-46. PubMed ID: 11420675
[TBL] [Abstract][Full Text] [Related]
44. Bryostatin 1: a potential anti-leukemic agent for chronic myelomonocytic leukemia.
Lilly M; Brown C; Pettit G; Kraft A
Leukemia; 1991 Apr; 5(4):283-7. PubMed ID: 2027297
[TBL] [Abstract][Full Text] [Related]
45. Upregulation of the TGFbeta signalling pathway by Bcr-Abl: implications for haemopoietic cell growth and chronic myeloid leukaemia.
Møller GM; Frost V; Melo JV; Chantry A
FEBS Lett; 2007 Apr; 581(7):1329-34. PubMed ID: 17349636
[TBL] [Abstract][Full Text] [Related]
46. The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia.
Marley SB; Deininger MW; Davidson RJ; Goldman JM; Gordon MY
Exp Hematol; 2000 May; 28(5):551-7. PubMed ID: 10812245
[TBL] [Abstract][Full Text] [Related]
47. The differentiation inducing effect of bryostatin 5 on human myeloid blast cells is potentiated by vitamin D3.
van der Hem KG; Dräger AM; Huijgens PC; Tol C; Devillé W; Langenhuijsen MM
Leukemia; 1994 Feb; 8(2):266-73. PubMed ID: 7508534
[TBL] [Abstract][Full Text] [Related]
48. Varied differentiation responses of human leukemias to bryostatin 1.
Kraft AS; William F; Pettit GR; Lilly MB
Cancer Res; 1989 Mar; 49(5):1287-93. PubMed ID: 2917358
[TBL] [Abstract][Full Text] [Related]
49. [Proliferative activity of granulocyte progenitors from the bone marrow of patients with chronic myeloid leukemia in 14-day culture in vivo].
Hansz J; Kozłowska-Skrzypczak M
Acta Haematol Pol; 1989; 20(1):29-35. PubMed ID: 2618564
[TBL] [Abstract][Full Text] [Related]
50. Successful treatment of murine melanoma with bryostatin 1.
Schuchter LM; Esa AH; May S; Laulis MK; Pettit GR; Hess AD
Cancer Res; 1991 Jan; 51(2):682-7. PubMed ID: 1985785
[TBL] [Abstract][Full Text] [Related]
51. The action of bryostatin on normal human hematopoietic progenitors is mediated by accessory cell release of growth factors.
Sharkis SJ; Jones RJ; Bellis ML; Demetri GD; Griffin JD; Civin C; May WS
Blood; 1990 Aug; 76(4):716-20. PubMed ID: 2200537
[TBL] [Abstract][Full Text] [Related]
52. Bryostatin 1 modulates the proliferation and lineage commitment of human myeloid progenitor cells exposed to recombinant interleukin-3 and recombinant granulocyte-macrophage colony-stimulating factor.
Li F; Grant S; Pettit GR; McCrady CW
Blood; 1992 Nov; 80(10):2495-502. PubMed ID: 1421372
[TBL] [Abstract][Full Text] [Related]
53. Modulation by bryostatin 1 of the in vitro radioprotective effects of the GM-CSF/IL-3 fusion protein, PIXY 321, on normal human myeloid progenitors.
Grant S; Traylor R; Pettit GR; Lin PS
Cytokine; 1993 Sep; 5(5):490-7. PubMed ID: 8142605
[TBL] [Abstract][Full Text] [Related]
54. Biological and chemical selection of Ph-negative clones.
Carlo-Stella C; Mangoni L; Piovani G; Garau D; Almici C; Rizzoli V
Stem Cells; 1993 Oct; 11 Suppl 3():77-82. PubMed ID: 8298479
[TBL] [Abstract][Full Text] [Related]
55. Primary acute myeloid leukaemia blasts resistant to cytokine-induced differentiation to dendritic-like leukaemia cells can be forced to differentiate by the addition of bryostatin-1.
Roddie PH; Horton Y; Turner ML
Leukemia; 2002 Jan; 16(1):84-93. PubMed ID: 11840267
[TBL] [Abstract][Full Text] [Related]
56. Mutants of a multipotent hematopoietic cell line blocked in GM-CSF-induced differentiation are leukemogenic in vivo.
Just U; Spooncer E; Löhler J; Stocking C; Ostertag W; Dexter TM
Exp Hematol; 1994 Aug; 22(9):933-40. PubMed ID: 8062891
[TBL] [Abstract][Full Text] [Related]
57. Identification of Philadelphia-negative granulocyte-macrophage colony-forming units generated by stroma-adherent cells from chronic myelogenous leukemia patients.
Carlo-Stella C; Mangoni L; Piovani G; Garau D; Almici C; Rizzoli V
Blood; 1994 Mar; 83(5):1373-80. PubMed ID: 7509656
[TBL] [Abstract][Full Text] [Related]
58. Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells.
Allan EK; Holyoake TL; Craig AR; Jørgensen HG
Leukemia; 2011 Jun; 25(6):985-94. PubMed ID: 21468038
[TBL] [Abstract][Full Text] [Related]
59. Mimicry of bryostatin 1 induced phosphorylation patterns in HL-60 cells by high-phorbol ester concentrations.
Warren BS; Kamano Y; Pettit GR; Blumberg PM
Cancer Res; 1988 Nov; 48(21):5984-8. PubMed ID: 3167850
[TBL] [Abstract][Full Text] [Related]
60. The involvement of "tumor suppressor" p53 in normal and chronic myelogenous leukemia hemopoiesis.
Bi S; Lanza F; Goldman JM
Cancer Res; 1994 Jan; 54(2):582-6. PubMed ID: 8275497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
